Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).

Gaye, Elisabeth; Penel, Nicolas; Lebellec, Loic

Document type :

Article dans une revue scientifique: Article original

DOI :

10.1097/CCO.0000000000000873

PMID :

35943424

Permalink :

http://hdl.handle.net/20.500.12210/90014

Title :

Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).

Author(s) :

Gaye, Elisabeth [Auteur]
Service d'oncologie médicale (CHRU Lille)
Penel, Nicolas [Auteur]

Service d'oncologie médicale (CHRU Lille)
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Lebellec, Loic [Auteur]
Service d'oncologie médicale (CHRU Lille)

Journal title :

Current Opinion in Oncology

Abbreviated title :

Curr Opin Oncol

Publication date :

2022-08-10

ISSN :

1531-703X

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Purpose of review Human epidermal growth factor 2 (HER2) alterations (protein overexpression, gene amplification and mutation) play a key role in oncogenesis and are more likely correlated to poorer outcome in solid ...
Show more >Purpose of review Human epidermal growth factor 2 (HER2) alterations (protein overexpression, gene amplification and mutation) play a key role in oncogenesis and are more likely correlated to poorer outcome in solid tumors. We reviewed recently published studies in the last 18 months on novel treatment approaches for HER2 positive solid tumors (excluding breast cancer). Recent findings Results of clinical studies assessing anti-HER2 therapies have been recently issued. One of the most promising drugs is transtuzumab deruxtecan, an antibody–drug conjugate which demonstrated clinically meaningful activity in gastric or gastroesophageal junction cancer and colorectal cancers. Small molecules such as poziotinib, pyrotinib, neratinib, which target both epidermal growth factor receptor (EGFR) and HER2 also showed promising activity, especially in heavily pretreated ERRB2-mutated non-small cell lung cancer (NSCLC) cancer patients. Yet, these findings need to be confirmed in confirmatory randomized trials with larger cohorts. Trastuzumab-based combinations with chemotherapy or immune checkpoint inhibitors are under development with promising results, but not in all HER2 tumors. Emerging adverse events with anti-HER2 are interstitial pneumopathy and diarrhea. Summary Tyrosine kinase inhibitors, antibody drug conjugate in monotherapy and combinations are emerging strategies in many HER2-positive cancers; HER2 therapies are now part of standard of care of HER2-amplified gastric or gastroesophageal junction cancer. Data are pending on several unmet medical needs.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T03:33:37Z
2024-01-09T13:28:32Z

Version	Link	Modification date
3	20.500.12210/90014	2024-01-10T08:05:46Z
2	20.500.12210/90014.2*	2024-01-09T13:24:42Z
1	20.500.12210/90014.1	2023-11-15T03:33:37Z

Novel treatment approaches for HER2 positive ...

BibTeX

CSV

Excel

RIS

Notice

Version history

Novel treatment approaches for HER2 positive ... BibTeX CSV Excel RIS

Notice

Version history

Novel treatment approaches for HER2 positive ...

BibTeX

CSV

Excel

RIS